Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America

Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America

Background: Developing countries have an estimate of ten times more approved biosimilars than developed countries. This disparity demands the need of an objective regulation that incorporates health policies according to the technological and economical capabilities of each country. One of the chall...

Full description

Saved in:
Bibliographic Details
Main Authors: Mendoza-Macedo,Karina, Romero-Díaz,Alexis J, Miranda-Hernández,Mariana P, Campos-García,Víctor R, Ramírez-Ibañez,Nancy D, Juárez-Bayardo,L. Carmina, Moreno-Duran,Karen, Cedillo-Robles,Miriam S, Pérez,Nestor O, Jung-Cook,Helgi, Flores-Ortiz,Luis F, Medina-Rivero,Emilio
Language:English
Published: Pontificia Universidad Católica de Valparaíso 2016
Subjects:
Bio therapeutic
Comparability
Critical quality attributes
Developing countries
Generics
Health policies
High quality biosimilars
Regulation
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582016000600010
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582016000600010

Similar Items